Mounjaro might be the name on everyone’s lips following impressive recent results in obesity with the GIP/GLP-1, but a much earlier Lilly asset, LY3437943, is also worth keeping an eye on. The project is a so-called triple-G – an agonist of GIP, GLP-1 and glucagon receptors – and data from a phase 1 trial, presented at ADA yesterday, are encouraging. Though primarily a safety study of ascending weekly doses in a type 2 diabetes population, the study also measured blood sugar and weight. After three months’ treatment, mean HbA1c decreased from baseline in all groups, with higher doses of LY3437943 showing statistically significant placebo-adjusted decreases of up to 1.56%. The agent also prompted dose-dependent decreases in mean placebo-adjusted body weight of up to 8.96kg, and safety seemed acceptable, with the most common treatment-emergent adverse events being nausea and diarrhoea, which were mostly mild. The lack of a dose response on the HbA1c endpoint is perhaps puzzling, though patients numbers were small, with only nine to 12 subjects in each LY3437943 arm. Data from two larger phase 2 trials in diabetes and obesity could come this year, and might clarify the situation.
| Clinical trials of LY3437943 | |||
|---|---|---|---|
| Status | Details | Data | NCT ID |
| Phase 2 | Vs pbo in 494 patients w obesity/overweight | PCD May 2022 | NCT04881760 |
| Phase 2 | Vs Trulicity and pbo in 300 patients w type 2 diabetes | PCD Jul 2022 | NCT04867785 |
| Phase 1 | Vs pbo in 64 Japanese participants w type 2 diabetes | PCD Dec 2022 | NCT04823208 |
| Phase 1 | Vs Trulicity and pbo in 72 patients w type 2 diabetes | Hit at ADA 2022 | NCT04143802 |
| Phase 1 | Vs pbo in 45 healthy participants | Completed | NCT03841630 |
| PCD = primary completion date. Source: Evaluate Pharma. https://www.evaluate.com/vantage/articles/news/trial-results-snippets/ada-2022-lillys-triple-g-one-watch | |||
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.